BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18076345)

  • 1. Efficacy and safety of bimatoprost/timolol fixed combination in the treatment of glaucoma or ocular hypertension.
    Martinez A; Sanchez M
    Expert Opin Pharmacother; 2008 Jan; 9(1):137-43. PubMed ID: 18076345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study.
    Ozturk F; Ermis SS; Inan UU
    Acta Ophthalmol Scand; 2007 Feb; 85(1):80-3. PubMed ID: 17244215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 24-hour efficacy of the bimatoprost-timolol fixed combination versus latanoprost as first choice therapy in subjects with high-pressure exfoliation syndrome and glaucoma.
    Konstas AG; Holló G; Mikropoulos DG; Haidich AB; Dimopoulos AT; Empeslidis T; Teus MA; Ritch R
    Br J Ophthalmol; 2013 Jul; 97(7):857-61. PubMed ID: 23686322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 6-month assessment of bimatoprost 0.03% vs timolol maleate 0.5%: hypotensive efficacy, macular thickness and flare in ocular-hypertensive and glaucoma patients.
    Martin E; Martinez-de-la-Casa JM; Garcia-Feijoo J; Troyano J; Larrosa JM; Garcia-Sanchez J
    Eye (Lond); 2007 Feb; 21(2):164-8. PubMed ID: 16254590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension.
    Robin AL
    Eur J Ophthalmol; 2007; 17(4):685-6; author reply 686-7. PubMed ID: 17671954
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4.
    Williams RD; Cohen JS; Gross RL; Liu CC; Safyan E; Batoosingh AL;
    Br J Ophthalmol; 2008 Oct; 92(10):1387-92. PubMed ID: 18621791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma.
    Konstas AG; Holló G; Mikropoulos D; Tsironi S; Haidich AB; Embeslidis T; Georgiadou I; Irkec M; Melamed S
    Br J Ophthalmol; 2010 Feb; 94(2):209-13. PubMed ID: 19825835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bimatoprost and bimatoprost/timolol fixed combination in patients with open-angle glaucoma and ocular hypertension.
    Katsanos A; Dastiridou AI; Fanariotis M; Kotoula M; Tsironi EE
    J Ocul Pharmacol Ther; 2011 Feb; 27(1):67-71. PubMed ID: 21214361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and efficacy of bimatoprost/timolol fixed combination: a 1-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension.
    Lewis RA; Gross RL; Sall KN; Schiffman RM; Liu CC; Batoosingh AL;
    J Glaucoma; 2010 Aug; 19(6):424-6. PubMed ID: 19855289
    [No Abstract]   [Full Text] [Related]  

  • 11. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension.
    Cohen JS; Gross RL; Cheetham JK; VanDenburgh AM; Bernstein P; Whitcup SM
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S45-52. PubMed ID: 15016561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial.
    Goldberg I; Gil Pina R; Lanzagorta-Aresti A; Schiffman RM; Liu C; Bejanian M
    Br J Ophthalmol; 2014 Jul; 98(7):926-31. PubMed ID: 24667994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension.
    Hommer A;
    Eur J Ophthalmol; 2007; 17(1):53-62. PubMed ID: 17294383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Travoprost/timolol fixed combination.
    Herceg M; Noecker R
    Expert Opin Pharmacother; 2008 Apr; 9(6):1059-65. PubMed ID: 18377347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bimatoprost/timolol: a review of its use in glaucoma and ocular hypertension.
    Curran MP; Orman JS
    Drugs Aging; 2009; 26(2):169-84. PubMed ID: 19220073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
    Stewart WC; Konstas AG; Nelson LA; Kruft B
    Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modern alchemy: fixed combinations of glaucoma drugs.
    Katz LJ
    Am J Ophthalmol; 2005 Jul; 140(1):125-6. PubMed ID: 16038653
    [No Abstract]   [Full Text] [Related]  

  • 18. A multicentre evaluation of the effect of patient education on acceptance of hyperaemia associated with bimatoprost therapy for glaucoma or ocular hypertension.
    Trattler W; Noecker RJ; Earl ML
    Adv Ther; 2008 Mar; 25(3):179-89. PubMed ID: 18351298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, tolerability and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% in a broad patient population: multicenter, open-label observational study.
    Feuerhake C; Buchholz P; Kimmich F
    Curr Med Res Opin; 2009 Apr; 25(4):1037-43. PubMed ID: 19290780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of bimatoprost for the treatment of open-angle glaucoma and ocular hypertension: a three-month, open-label study in community-based practices in Thailand.
    Wanichwecha-Rungruang B; Iemsomboon W
    J Med Assoc Thai; 2005 Sep; 88(9):1228-35. PubMed ID: 16536109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.